+49.5%
RKLB vs MRNA
+511.3%
-461.8%
-61.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.7% | -2.2% | +2.9% | +0.8% |
| 7D | -0.2% | +5.5% | -5.7% | -0.5% |
| 30D | -14.1% | +158.7% | -172.8% | -24.7% |
| 3M | -46.4% | +182.1% | -228.6% | -55.4% |
| 6M | -10.6% | +151.8% | -162.5% | -22.9% |
| YTD | -7.9% | +393.6% | -401.4% | -35.8% |
| 1Y | +49.5% | +499.5% | -450.0% | +8.2% |
| All | +49.5% | +511.3% | -461.8% | +8.2% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling